Recent investigations have focused on the intersection of GLP|GIP|glucagon receptor agonist therapies and DA signaling. While GCGR activators are increasingly employed for treating type 2 diabetes mellitus, their https://semaglutide643724.luwebs.com/42876062/novel-gcgr-agonists-and-dopaminergic-adjustment-a-contextual-assessment